Long-Term Specified Drug Use-results Survey of Betanis Tablets
This trial has been completed.
|Sponsor||Astellas Pharma Inc|
|Start date||October 2012|
|End date||September 2016|
|Trial size||1263 participants|
|Trial identifier||NCT01901120, BE0002|
This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Chubu, Japan||not available||completed|
|Chugoku, Japan||not available||completed|
|Hokkaido, Japan||not available||completed|
|Kansai, Japan||not available||completed|
|Kanto, Japan||not available||completed|
|Kyushu, Japan||not available||completed|
|Shikoku, Japan||not available||completed|
|Tohoku, Japan||not available||completed|
the usual adult dosage of mirabegron once daily after a meal
Occurrence of adverse events
time frame: Up to 36 months after treatment
Overactive Bladder Symptom Score (OABSS)
time frame: At the start of treatment and 3, 6, 12, 18, 24, 30, and 36 months after treatment
Male or female participants of any age.
Inclusion Criteria: - Patients who administer mirabegron for treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder and also who have no treatment history of mirabegron.
|Official title||Long-Term Specified Drug Use-results Survey of Betanis Tablets|
Call for more information